Sign in to view content

Results from Part 1 of the Phase 2/3 SIGLEC Trial Assessing AVD-104 for Geographic Atrophy: Glyco-immunologic Modulation of Macrophage Activity

Rishi P. Singh, MD

Video
Published 2024

Related

Assessing Characteristics of Patients With or Without Intraocular Inflammation (IOI) In the Brolucizumab Treatment Arms From the HAWK and HARRIER, Phase 3 Studies
Jeffrey S. Heier, MD
Updates from the Field
2020
Inhibition of Complement C3 in GA with NGM621: Phase 1 Study Results
David A. Eichenbaum, MD, FASRS
Updates from the Field
2021
Single Intraoperative Subconjunctival Triamcinolone Acetonide Injection Versus 4-6-Week Topical Steroid Taper Following Vitreore
Elizabeth A Atchison, MD
Updates from the Field
2018

Category: AMD-Non-Neovascular

See more